title: Diagnostic use of anti-modified nucleoside monoclonal antibody.
abstract: By use of monoclonal antibodies (MoAbs) termed APU-6 and AMA-2, we determined the usefulness of urinary modified nucleosides, pseudouridine and 1-methyladenosine, as markers for malignancy. In patients with leukemia and other forms of cancer, these nucleosides elevated significantly and reflected the disease status of patients. The immunohistochemical analysis showed that cancer cells were specifically stained with the MoAbs. Chemical identification of the cellular components reactive with the MoAbs revealed that APU-6-associated antigens were mainly rRNA and AMA-2-associated antigens were mainly tRNA. These results suggest that APU-6 and AMA-2 would be useful tools for clinical and biological studies of cancer.
authors.affiliation: Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai.
authors.forename: K
authors.initials: K
authors.lastname: Itoh
authors.forename: S
authors.initials: S
authors.lastname: Ishiwata
authors.forename: N
authors.initials: N
authors.lastname: Ishida
authors.forename: M
authors.initials: M
authors.lastname: Mizugaki
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000652:urine; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D014408:Biomarkers, Tumor / Q000652:urine*; D006801:Humans; D007124:Immunoenzyme Techniques; D007938:Leukemia / Q000652:urine*; D008223:Lymphoma / Q000652:urine*; D008991:Monitoring, Physiologic / Q000379:methods; D011560:Pseudouridine / Q000652:urine*
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D011560:Pseudouridine; C002230:1-methyladenosine; D000241:Adenosine